News
Peplin `positive' on trial of sun spot treatment
A Brisbane skin-cancer biotech reports successful late-stage results for its sun-spot gel, saying it remains on schedule for a US regulatory filing and a 2011 market launch.
Australian General Manager, Peplin Inc
| Role | Organisation | Sources |
|---|---|---|
| Australian General Manager | Peplin Inc | GBS Ventures (Thu 12 Nov 2009), GBS Ventures (Tue 19 May 2009), GBS Ventures (Thu 8 Jan 2009) |
Stories naming Dr Peter Welburn. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
A Brisbane skin-cancer biotech reports successful late-stage results for its sun-spot gel, saying it remains on schedule for a US regulatory filing and a 2011 market launch.
Peplin reports its PEP005 gel met the primary endpoint in a Phase IIb actinic keratosis trial, clearing lesions safely across doses and moving toward Phase III development.